Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S is dated February 10, 2026. The report discloses transactions in company shares by board members, executives, and associated persons in compliance with Article 19 of Regulation No. 596/2014 on market abuse. Novo Nordisk is a global healthcare company headquartered in Denmark, focusing on defeating serious chronic diseases, particularly diabetes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
| Metric | Value |
|---|---|
| Transaction Type | Sale of shares (to cover tax on Long Term Incentive programme) |
| Volume | 22,000 shares |
| Price per Share | DKK 319.80 |
| Total Value | DKK 7,035,600 |
| Transaction Date | February 9, 2026 |
| Exchange | Nasdaq Copenhagen |
Material Changes
The filing text does not provide a clear value for material changes in financial performance versus the prior comparable period. The only reported change is the specific share transaction by an executive.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on strategy, or specific risk factors. The document contains a standard corporate description stating the company employs approximately 68,800 people in 80 countries and markets products in around 170 countries.
Important Facts for Investors to Verify
- Executive Identity: The transaction was executed by Martin Holst Lange, Executive Vice President, R&D and Chief Scientific Officer (CSO).
- Transaction Purpose: The sale was specifically to cover tax obligations on shares transferred under the Long Term Incentive programme, not a discretionary open-market sale.
- Share Class: The transaction involved Novo Nordisk B shares (ISIN: DK0062498333).
- Market Context: The transaction occurred on Nasdaq Copenhagen at a price of DKK 319.80 per share.